Skip to content

Benefit of injection magnesium sulphate in patient with increased shortness of breath in COPD patients

The effect of intravenous magnesium sulphate in acute exacerbation of chronic obstructive pulmonary disease patient requiring non-invasive ventilation support: a randomized clinical trial - nil

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/066775
Enrollment
80
Registered
2024-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J441- Chronic obstructive pulmonary disease with (acute) exacerbation

Interventions

Intervention1: magnesium sulphate: Patients of acute exacerbation of COPD in experimental group will receive intravenous infusion of 2gram of magnesium sulphate in 100ml of normal saline over 30 minu

Sponsors

All India Institute of Medical Sciences Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patient of AECOPD with following criteria’s a)pH less than 7.35, pCO2 more than 45 mm hg. or b)persistent hypoxemia despite supplemental oxygen therapy. [persistent hypoxemia that is patient not able to maintain more than 88% after 15 min of NRBM (15L per minute O2) or c)severe dyspnea with clinical signs suggestive of respiratory muscle fatigue, increased of work of breathing or both, such as use of respiratory accessory muscles paradoxical motion of the abdomen or retraction of intercostal spaces.

Exclusion criteria

Exclusion criteria: a)Patient with contraindication for use of mgso4 { hypersensitivity ,diabetic coma ,heart block, myocardial damage , dyselectrolytemia such as hypomagnesemia ,hypercalcemia) b) use of I.V. mgso4 in past 24 hours c)using medication that contain magnesium d)pregnant women e) pneumonia, pleural or pericardial effusion, pneumothorax, heart failure renal failure, sepsis. f) Haemodynamically unstable patient g) Patient requiring immediate endotracheal intubation. h) Uncooperative patient i) Did not consent to participate

Design outcomes

Primary

MeasureTime frame
1. Respiratory rate improvement 2. ABG parameters: arterial pH and pCO2 improvement. Timepoint: baseline, 1 hr,4hr,12hr,24hr

Secondary

MeasureTime frame
a)NIV failure rate and rate endotracheal intubation. b)Duration of NIV requirement in both groups. c)Length of hospital stay Timepoint: NIV failure rate and rate endotracheal intubationation at 24hour after start of treatment

Countries

India

Contacts

Public ContactSADANANDA BARIK

AIIMS BHUBANESWAR

tem_sadananda@aiimsbhubaneswar.edu.in9764048831

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026